Research Updates

Back to feed
Clinical trials
Registered study

High importance

Sep 28, 2026

Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study

View original source

Why it matters

This research provides critical insights into the challenges faced by women with rare vascular genetic disorders during pregnancy and underscores the importance of developing targeted clinical guidelines to enhance maternal and fetal health outcomes.

Objective

To analyze and understand obstetrical complications associated with rare maternal vascular genetic disorders, specifically focusing on Hereditary Hemorrhagic Telangiectasia (HHT) and related conditions to improve maternal and fetal health outcomes.

Results

Preliminary findings indicate a higher incidence of complications in pregnant women with HHT, including increased risk of hemorrhage and other vascular-related issues, emphasizing the need for specialized care during pregnancy.

Methods

The study involved a national prospective cohort design where pregnant women diagnosed with rare multisystemic vascular diseases were monitored throughout their pregnancies to collect data on health complications and outcomes.

Limitations

The study's findings may be limited by sample size and the rarity of the conditions, which could affect the generalizability of the results across wider populations with different demographics or health systems.

For your doctor:

ClinicalTrials.gov: NCT04194619

Abstract

There are no prospective studies of pregnancies for the diseases studied here in (Heredity Hemorrhagic Telangiectasia, Marfan syndrome or related, primary lower limb lymphedema, superficial arteriovenous malformations, and cerebro-spinal arteriovenous malformations) although complications of these can present life-threatening health problems for the mother and her baby. The purpose of this National prospective study is to obtain greater insight into obstetrical complications associated with rare maternal vascular genetic disorders in order to improve prevention and to reduce risk of death. In this context, experts and patient associations consider that there is a need to make real progress in the formulation of recommendations based on scientific data.